StockUS listing USGNPXNASDAQHealthcareCapital Destroyer

Genprex Inc(GNPX) Stock Analysis | Healthcare

USD --+0.00%
Reward31Low
Risk45Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.94M
Reward Ratingⓘ31 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ45 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GNPX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Genprex Inc?

, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.

AI Brief Pro

The brief on Genprex Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Genprex Inc?

, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.94M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Low (31)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio0.0147
Beta-0.992
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.